Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 12:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 2,513 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: RAPID Clear all

Conditions: Obesity, Diabetes
Interventions: slowly digestible carbohydrate; Dietary Supplement
Lead sponsor: Purdue University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Healthy Subjects
Interventions: CPI-444 Capsules, CPI-444 Tablets; Drug
Lead sponsor: Corvus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Sepsis
Interventions: Conservative Fluid Management Strategy; Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Obesity, Blood Glucose, High
Interventions: Micronutrient-dense plant-rich Intervention; Behavioral
Lead sponsor: Northern Arizona University; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Flagstaff, Arizona

Conditions: Diabetes, Coronary Artery Calcification
Interventions: Not listed
Lead sponsor: VeraLight, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Hepatitis C, Chronic
Interventions: Copegus, Pegasys, RO5024048; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 21
States / cities: Birmingham, Alabama • La Jolla, California • Sacramento, California + 18 more

Conditions: HIV Infections
Interventions: TERA Intervention (TERA), Standard of Care (SOC); Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 13 Years to 24 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 8
States / cities: Aurora, Colorado • Fort Lauderdale, Florida • Jacksonville, Florida + 5 more

Conditions: Chronic Kidney Disease, Acute Kidney Injury
Interventions: 75 mg / 6 mL VFI™; Device
Lead sponsor: FAST BioMedical; Industry
Eligibility: 19 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cervical Intraepithelial Neoplasia Grade 2/3
Interventions: FRD, Cytology, HPV testing, Colposcopy, ECC, Biospy; Combination Product · Other · Procedure
Lead sponsor: GY Highland Biotech LLC; Industry
Eligibility: 20 Years to 60 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Gastric Antral Vascular Ectasia, Cirrhosis, Chronic Kidney Disease
Interventions: Gastric Emptying Breath Test; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 19 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Conscious Sedation, Simple Lacerations Less Than 4 cm, Lumbar Punctures, Minor Incision Drainage of Abscesses Not Requiring Extensive Debridement
Interventions: Nitrous Oxide, Midazolam; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 2 Years to 17 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Blunt Trauma to Abdomen, Wounds and Injuries, Abdomen Injury, Abdominal Injury, Abdomen, Acute
Interventions: Focused Assessment with Sonography for Trauma (FAST) Examination, No Intervention: Standard of Care - Without the FAST Examination; Diagnostic Test · Other
Lead sponsor: University of California, Davis; Other
Eligibility: Up to 17 Years
Enrollment: 4,650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 6
States / cities: Sacramento, California • Aurora, Colorado • Atlanta, Georgia + 3 more

Conditions: Healthy Volunteers
Interventions: AMG 378, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: Lake Forest, California • Overland Park, Kansas

Conditions: Type 1 Diabetes Mellitus
Interventions: Tandem t:slim X2 with Control-IQ Technology + Dexcom G6, Dexcom CGM G5, Continuous Subcutaneous Insulin Infusion; Device
Lead sponsor: University of Virginia; Other
Eligibility: 6 Years to 18 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Stanford, California • Aurora, Colorado • Charlottesville, Virginia

Conditions: Respiratory Distress Syndrome (RDS)
Interventions: LISA combination product (Curosurf+catheter CHF6440), Curosurf through conventional administration (endotracheal tube); Combination Product · Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 30 Minutes to 24 Hours
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 26
States / cities: Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 22 more

Conditions: Treatment Resistant Depression, MDD, Major Depressive Disorder, Recurrent Depression, Depression
Interventions: Psilocybin, Accelerated intermittent theta burst (aiTBS) rTMS treatment, Low-dose psilocybin, Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment; Drug · Device
Lead sponsor: University of Texas at Austin; Other
Eligibility: 22 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Coronary Artery Disease
Interventions: PET-MPI Protocol, CT-MPI, Coronary CT angiography (CCTA) for CT-FFR calculation, Regadenoson; Diagnostic Test · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Major Depressive Disorder
Interventions: L-Leucine, Maltodextrin; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 64 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Vitamin D Deficiency
Interventions: cholecalciferol; Dietary Supplement
Lead sponsor: Tufts University; Other
Eligibility: 50 Years to 69 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stroke, Aphasia, Language
Interventions: Transcranial Magnetic Stimulation; Device
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 85 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
Interventions: Toripalimab, Carboplatin, Cisplatin, Paclitaxel, Radiation Therapy; Drug · Radiation
Lead sponsor: Matthew Spector; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Moderate Hepatic Impairment
Interventions: Pexidartinib; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: PVD, Arterial Ulcers
Interventions: High pressure intermittent pneumatic compression (HPIPC), Excercise; Device · Behavioral
Lead sponsor: Calvary Hospital, Bronx, NY; Other
Eligibility: 18 Years to 90 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Hemodynamic Instability, Respiratory Failure
Interventions: Ultrasound; Other
Lead sponsor: Beth Israel Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Crossover Trials Which Assessed Consumption of Slowly Digestible Carbohydrates for 21 Days on Gastric Emptying Rates

Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female Subjects

A Randomized Controlled Trial of a Conservative Fluid Balance Strategy for Patients With Sepsis and Cardiopulmonary Dysfunction (BALANCE Study)

A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans

A Study Comparing Skin Fluorescence to Coronary Artery Calcification

A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4

Triggered Escalating Real-time Adherence (TERA) Intervention

FAST GFR: Pilot Study to Evaluate the Safety of the FAST GFR Test in Patients.

The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Lesion Detection

Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias

A Comparison of Intranasal Midazolam and Nitrous Oxide (N2O) Minimal Sedation for Minor Procedures in a Pediatric Emergency Department

A Research Study of Abdominal Ultrasound (FAST) in Children With Blunt Torso Trauma

Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants

Artificial Pancreas and Remote Monitoring During a T1DM Youth Ski Camp

A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Administration Through Less Invasive Surfactant Administration (LISA) and Conventional Administration

Psilocybin rTMS for Treatment Resistant Depression

The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI

Rapid Antidepressant Effects of Leucine

The Effect of a Meal on Vitamin D Absorption

Language Processing and TMS

Window of Opportunity in Preserving Laryngeal Function Trial

Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

Effect of HPIPC for the Treatment of Ischemic Ulcers in Subjects With PAD

Efficacy of Ultrasound to Guide Management During a Rapid Response Event